drugset
drugset / Trial / NCT00792558

Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers

NCT00792558 ↗

Phase 1 Withdrawn Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the maximum tolerated dose of BMS-817378 in subjects with advanced cancers

Timeline

Start
2009-01
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-817378 Unknown 25 mg Oral

Indications

cancer